Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States

Corporate Breaking News

Home : Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States

May 05 2020	Isofol's Drug Candidate Arfolitixorin Receives Additional Clinical Patent Approval in the United States
GOTHENBURG, Sweden, May 5, 2020 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States. The patent expires in 2038 and is a divisional patent for the master patent...


Source:https://www.prnewswire.com:443/news-releases/isofols-drug-candidate-arfolitixorin-receives-additional-clinical-patent-approval-in-the-united-states-301052612.html

Related News
» Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference » Proxymity launches consortium of financial industry leaders and raises $20.5 million in strategic round to become its own entity